AbbVie, Inc., North Chicago, Illinois (Dr Mittal and Dr Shah); Analysis Group, Inc., Boston, Massachusetts (Dr Yang, Dr Gao, and Mr Carley); Case Western Reserve University School of Medicine, Cleveland, Ohio (Dr Sherman).
J Occup Environ Med. 2021 Oct 1;63(10):e724-e731. doi: 10.1097/JOM.0000000000002354.
The aim of this study was to evaluate the impact of adherence to adalimumab on all-cause work loss, healthcare resource utilization (HRU), and direct medical and indirect costs over 2 years using real-world data.
This was a retrospective cohort study using a large, United States administrative claims database. Adult patients treated with adalimumab were grouped into adherent and non-adherent cohorts and followed for up to 2 years. Outcomes were compared between cohorts.
Over 2 years, adherent patients had $10,214 lower per patient medical and indirect costs compared to non-adherent patients, resulting from lower HRU, fewer days of absenteeism, and lower rates of work loss events.
Patient and societal benefits of adherence to adalimumab are significant over 2 years. These findings highlight the importance of policies aimed at improving adherence to self-administrated medications.
本研究旨在利用真实世界数据评估阿达木单抗治疗的依从性对全因工作损失、医疗资源利用（HRU）和直接医疗及间接成本的影响。
这是一项回顾性队列研究，使用了一个大型的美国行政索赔数据库。接受阿达木单抗治疗的成年患者被分为依从性和非依从性队列，并随访长达 2 年。对队列间的结果进行了比较。
在 2 年内，依从性患者的每位患者的医疗和间接成本比非依从性患者低 10214 美元，这归因于较低的 HRU、缺勤天数减少以及工作损失事件的发生率降低。
阿达木单抗治疗的依从性在 2 年内对患者和社会都有显著的获益。这些发现强调了旨在提高自我管理药物依从性的政策的重要性。
